[go: up one dir, main page]

WO2007023310A3 - Stimulation of neurogenesis with help of alk inhibitors - Google Patents

Stimulation of neurogenesis with help of alk inhibitors Download PDF

Info

Publication number
WO2007023310A3
WO2007023310A3 PCT/GB2006/050244 GB2006050244W WO2007023310A3 WO 2007023310 A3 WO2007023310 A3 WO 2007023310A3 GB 2006050244 W GB2006050244 W GB 2006050244W WO 2007023310 A3 WO2007023310 A3 WO 2007023310A3
Authority
WO
WIPO (PCT)
Prior art keywords
alk
neurogenesis
stimulation
help
alk inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/050244
Other languages
French (fr)
Other versions
WO2007023310A2 (en
Inventor
James George Bilsland
Ignacio Munoz-Sanjuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of WO2007023310A2 publication Critical patent/WO2007023310A2/en
Publication of WO2007023310A3 publication Critical patent/WO2007023310A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for increasing neurogenesis in the brain by administering an inhibitor of anaplastic lymphoma kinase (ALK), the treatment of cognitive dysfunction and depression disorders by administering an inhibitor of ALK, an assay for determining inhibitors of ALK, and inhibitors of ALK.
PCT/GB2006/050244 2005-08-25 2006-08-18 Stimulation of neurogenesis with help of alk inhibitors Ceased WO2007023310A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0517329.9A GB0517329D0 (en) 2005-08-25 2005-08-25 Stimulation of neurogenesis
GB0517329.9 2005-08-25

Publications (2)

Publication Number Publication Date
WO2007023310A2 WO2007023310A2 (en) 2007-03-01
WO2007023310A3 true WO2007023310A3 (en) 2007-08-23

Family

ID=35198339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/050244 Ceased WO2007023310A2 (en) 2005-08-25 2006-08-18 Stimulation of neurogenesis with help of alk inhibitors

Country Status (2)

Country Link
GB (1) GB0517329D0 (en)
WO (1) WO2007023310A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046402T2 (en) 2009-06-10 2020-03-30 Chugai Pharmaceutical Co Ltd Tetracyclic compounds
TWI526441B (en) 2010-08-20 2016-03-21 中外製藥股份有限公司 Composition comprising tetracyclic compounds
KR101582852B1 (en) * 2012-05-24 2016-01-07 서울대학교 산학협력단 Therapeutics for the treatment of neurodegenerative diseases mediated by Tau proteins
SG11201502211QA (en) 2012-09-25 2015-05-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
CN113416179A (en) 2014-04-25 2021-09-21 中外制药株式会社 Novel crystal of tetracyclic compound
MX386901B (en) 2014-04-25 2025-03-19 Chugai Pharmaceutical Co Ltd FORMULATION CONTAINING A LARGE AMOUNT OF TETRACYCLIC COMPOUND.
TWI803187B (en) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 Solid dispersion containing amorphous body of tetracyclic compound and preparation
TWI752901B (en) 2015-01-16 2022-01-21 日商中外製藥股份有限公司 Combined medicine
EP3848361B1 (en) 2018-09-04 2025-01-22 Chugai Seiyaku Kabushiki Kaisha Method of producing tetracyclic compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009389A2 (en) * 2003-07-23 2005-02-03 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2005016894A1 (en) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005026158A1 (en) * 2003-09-16 2005-03-24 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2006021454A2 (en) * 2004-08-27 2006-03-02 Novartis Ag Pyrimidine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009389A2 (en) * 2003-07-23 2005-02-03 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
WO2005016894A1 (en) * 2003-08-15 2005-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005026158A1 (en) * 2003-09-16 2005-03-24 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2006021454A2 (en) * 2004-08-27 2006-03-02 Novartis Ag Pyrimidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUNUGI H ET AL: "Possible association between nonsynonymous polymorphisms of the anaplastic lymphoma kinase (ALK) gene and schizophrenia in a Japanese population", JOURNAL OF NEURAL TRANSMISSION ; BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY, PARKINSON'S DISEASE AND ALLIED CONDITIONS, ALZHEIMER'S DISEASE AND ADOLESCENT PSYCHIATRY RELATED DISORDERS, BIOLOGICAL PSYCHIATRY, BIOLOGICAL CHILD AND ADOLESCENT PSYCHIAT, vol. 113, no. 10, 11 April 2006 (2006-04-11), pages 1569 - 1573, XP019444265, ISSN: 1435-1463 *

Also Published As

Publication number Publication date
GB0517329D0 (en) 2005-10-05
WO2007023310A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
WO2006081172A3 (en) Compounds and compositions as protein kinase inhibitors
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2008063558A3 (en) Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
WO2008127226A3 (en) P13 kinase antagonists
WO2005067901A3 (en) Methods for treating and preventing hypertension and hypertension-related disorders
WO2005012241A3 (en) p-38 KINASE INHIBITORS
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2005000351A3 (en) Combination therapy for b cell disorders
CY1112238T1 (en) ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE
WO2006015087A3 (en) Thalamic stimulation device
WO2007059257A3 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
WO2009089260A3 (en) Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
WO2005117938A3 (en) Methods of treating ocular conditions
WO2007073497A3 (en) Calcium channel antagonists
WO2005099702A3 (en) R(-)-11-hydroxyaporphine derivatives and uses thereof
WO2005039486A3 (en) Compounds and compositions as protein kinase inhibitors
NO20076186L (en) Mitotic kinesin inhibitors and methods for their use
WO2007137224A3 (en) Method of treatment
WO2007023310A3 (en) Stimulation of neurogenesis with help of alk inhibitors
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2007075852A3 (en) Calcium channel antagonists
EP1961447A3 (en) Treating depressive disorders with PKC activators
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06779598

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06779598

Country of ref document: EP

Kind code of ref document: A2